Literature DB >> 10601019

Cell type-specific activation of mitogen-activated protein kinases by CpG-DNA controls interleukin-12 release from antigen-presenting cells.

H Häcker1, H Mischak, G Häcker, S Eser, N Prenzel, A Ullrich, H Wagner.   

Abstract

Activation of antigen-presenting cells (APCs) by invariant constituents of pathogens such as lipopolysaccharide (LPS) or bacterial DNA (CpG-DNA) initiates immune responses. We have analyzed the mitogen-activated protein kinase (MAPK) pathways triggered by CpG-DNA and their significance for cytokine production in two subsets of APCs, i.e. macrophages and dendritic cells (DCs). We found that CpG-DNA induced extracellular signal-regulated kinase (ERK) activity in macrophages in a classic MEK-dependent way. This pathway up-regulated tumor necrosis factor production but down-regulated interleukin (IL)-12 production. However, in DCs, which produce large amounts of IL-12, CpG-DNA and LPS failed to induce ERK activity. Consistent with a specific negative regulatory role for ERK in macrophages, chemical activation of this pathway in DCs suppressed CpG-DNA-induced IL-12 production. Overall, these results imply that differential activation of MAP kinase pathways is a basic mechanism by which distinct subsets of innate immune cells regulate their effector functions.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10601019      PMCID: PMC1171760          DOI: 10.1093/emboj/18.24.6973

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  27 in total

Review 1.  The role of immunostimulatory CpG-DNA in septic shock.

Authors:  H Wagner; G B Lipford; H Häcker
Journal:  Springer Semin Immunopathol       Date:  2000

Review 2.  Immunostimulatory DNA sequences help to eradicate intracellular pathogens.

Authors:  H Wagner; H Häcker; G B Lipford
Journal:  Springer Semin Immunopathol       Date:  2000

3.  CD40 signaling in human dendritic cells is initiated within membrane rafts.

Authors:  P O Vidalain; O Azocar; C Servet-Delprat; C Rabourdin-Combe; D Gerlier; S Manié
Journal:  EMBO J       Date:  2000-07-03       Impact factor: 11.598

Review 4.  Activation of the immune system by bacterial CpG-DNA.

Authors:  Georg Häcker; Vanessa Redecke; Hans Häcker
Journal:  Immunology       Date:  2002-03       Impact factor: 7.397

5.  Interleukin-12: an update on its immunological activities, signaling and regulation of gene expression.

Authors:  Jianguo Liu; Shanjin Cao; Sunjung Kim; Elaine Y Chung; Yoichiro Homma; Xiuqin Guan; Violeta Jimenez; Xiaojing Ma
Journal:  Curr Immunol Rev       Date:  2005-06

6.  A20-binding inhibitor of NF-κB (ABIN1) controls Toll-like receptor-mediated CCAAT/enhancer-binding protein β activation and protects from inflammatory disease.

Authors:  Jingran Zhou; Ruiqiong Wu; Anthony A High; Clive A Slaughter; David Finkelstein; Jerold E Rehg; Vanessa Redecke; Hans Häcker
Journal:  Proc Natl Acad Sci U S A       Date:  2011-10-19       Impact factor: 11.205

7.  Influence of ERK activation on decreased chemotaxis of mature human cord blood monocyte-derived dendritic cells to CCL19 and CXCL12.

Authors:  Geling Li; Sunanda Basu; Myung-Kwan Han; Young-June Kim; Hal E Broxmeyer
Journal:  Blood       Date:  2006-12-19       Impact factor: 22.113

8.  Inactivation of JNK1 enhances innate IL-10 production and dampens autoimmune inflammation in the brain.

Authors:  Elise H Tran; Yasu-Taka Azuma; Manchuan Chen; Claire Weston; Roger J Davis; Richard A Flavell
Journal:  Proc Natl Acad Sci U S A       Date:  2006-08-28       Impact factor: 11.205

9.  Differential production of cytokines, reactive oxygen and nitrogen by bovine macrophages and dendritic cells stimulated with Toll-like receptor agonists.

Authors:  Dirk Werling; Jayne C Hope; Chris J Howard; Thomas W Jungi
Journal:  Immunology       Date:  2004-01       Impact factor: 7.397

10.  Interleukin-10 production by Th1 cells requires interleukin-12-induced STAT4 transcription factor and ERK MAP kinase activation by high antigen dose.

Authors:  Margarida Saraiva; Jillian R Christensen; Marc Veldhoen; Theresa L Murphy; Kenneth M Murphy; Anne O'Garra
Journal:  Immunity       Date:  2009-07-30       Impact factor: 31.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.